XML 28 R12.htm IDEA: XBRL DOCUMENT
v3.24.1

Licensed Rights and Other Intangible Assets | 12 Months Ended
--- | ---
Dec. 31, 2023
Licensed Rights and Other Intangible Assets [Abstract] |
Licensed rights and other intangible assets | 5. Licensed rights and other intangible assets The following provides information about our license rights and other intangible assets, net (in thousands):
|  | As of December 31, 2023 |  |  | As of December 31, 2022 |
|  | Gross |  |  |  |  |  |  |  |  | Gross |  |  |  |  |  |  |
|  | Carrying |  |  | Accumulated |  |  |  |  |  | Carrying |  |  | Accumulated |  |  |  |
|  | Amount |  |  | Amortization |  |  | Net |  |  | Amount |  |  | Amortization |  |  | Net |
Intangible assets subject to amortization: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Hormone therapy drug patents |  | $ | 6,818 |  |  | $ | 1,871 |  |  | $ | 4,947 |  |  | $ | 6,225 |  |  | $ | 1,598 |  |  | $ | 4,627 |
Hormone therapy drug patents applied and pending approval |  |  | 842 |  |  |  | — |  |  |  | 842 |  |  |  | 1,995 |  |  |  | — |  |  |  | 1,995 |
Intangible assets subject to amortization |  |  | 7,660 |  |  |  | 1,871 |  |  |  | 5,789 |  |  |  | 8,220 |  |  |  | 1,598 |  |  |  | 6,622 |
Intangible assets not subject to amortization: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Trademarks/trade name rights |  |  | 309 |  |  |  | — |  |  |  | 309 |  |  |  | 321 |  |  |  | — |  |  |  | 321 |
Intangible assets, net |  | $ | 7,969 |  |  | $ | 1,871 |  |  | $ | 6,098 |  |  | $ | 8,541 |  |  | $ | 1,598 |  |  | $ | 6,943 |
We recorded, in continuing operations, amortization expense related to patents of $0.8 million for 2023, of which $0.5 million is accelerated amortization as a result of a review of our intangible assets, and $0.6 million for 2022. We recorded amortization expense related to the exclusive license rights agreement with Population Council of $3.0 million for 2022, which was reclassified to discontinued operations after we completed transaction with Mayne Pharma in December 2022, and excluded from the table above. Our intangible assets subject to amortization are expected to be amortized as follows (in thousands):
Year ending December 31, |  |  |
2024 |  |  | 533 |
2025 |  |  | 445 |
2026 |  |  | 445 |
2027 |  |  | 445 |
2028 |  |  | 445 |
Thereafter |  |  | 5,347 |
Total |  | $ | 7,660 |
We use a combination of qualitative and quantitative factors to assess licensed rights and intangible assets for impairment. In the year ending December 31, 2023, we have not impaired any of our hormone therapy drug patent assets.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for all or part of the information related to intangible assets. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//350-30/tableOfContent + Details
Name: | us-gaap_IntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration